ISRCTN71502099 https://doi.org/10.1186/ISRCTN71502099

Radiation versus observation following surgical resection of atypical meningioma

Submission date 19/05/2014	**Recruitment status** No longer recruiting	[X] Prospectively registered [X] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 19/05/2014	**Overall study status** Ongoing	
Last Edited 26/07/2022	**Condition category** Cancer	

Plain English summary of protocol
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-radiotherapy-after-surgery-for-a-type-of-brain-tumour-called-meningioma-roam-eortc-1308

Contact information

Type(s)
Scientific

Contact name
Mr Michael Jenkinson

ORCID ID
https://orcid.org/0000-0003-4587-2139

Contact details
The Walton Centre NHS Foundation Trust
University of Liverpool
Lower Lane
Liverpool
United Kingdom
L9 7LJ

Type(s)
Public

Contact name
Ms Stephanie Willshaw

Contact details
Liverpool Clinical Trials Centre
University of Liverpool

2nd Floor Institute in the Park
Alder Hey Children's NHS Foundation Trust
Eaton Road
Liverpool
United Kingdom
L12 2AP
+44 (0)151 794 9766
roam@liverpool.ac.uk

Additional identifiers

Protocol serial number
HTA 12/173/14

Study information

Scientific Title
Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (the ROAM trial)

Acronym
ROAM

Study objectives
Current hypothesis as of 03/05/2017:
To determine whether early adjuvant fractionated radiotherapy reduces the risk of tumour recurrence or death due to any cause compared to active monitoring in newly diagnosed atypical meningioma.

Previous hypothesis:
To determine whether early adjuvant fractionated external beam radiotherapy reduces the risk of tumour recurrence compared to active monitoring in newly diagnosed atypical meningioma.

Ethics approval required
Old ethics approval format

Ethics approval(s)
NRES Committee North East - Newcastle & North Tyneside 2, 12/02/2015, ref: 15/NE/0013

Study design
Two-arm multi-centre randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Atypical meningioma

Interventions
The trial will randomise patients who have undergone gross total surgical resection of atypical (grade II) meningioma in a 1:1 ratio to either early radiotherapy (intervention) or active monitoring (comparator). Web-based randomisation will be used in this trial. Patients will be followed up for 60 months post randomisation by collecting information on signs/symptoms of tumour recurrence, 6 monthly MRI, recording of adverse events, quality of life questionnaires and cognitive function tests.

Intervention Type
Device

Phase
Phase III

Primary outcome(s)
Current primary outcome measure as of 05/04/2019:
Time to MRI evidence of tumour recurrence or death due to any cause (disease free survival [DFS]). (DFS will be counted from the date of surgery until the date of MRI evidence of tumour recurrence or death due to any cause. Only clear dural thickening as identified by the investigator is to be considered tumour.)

Previous primary outcome measure:
Time to MRI evidence of tumour recurrence [disease free survival (DFS)] is assessed at baseline, 6 and 12 months following surgery and annually thereafter for a minimum of 5 years post-surgery.

Key secondary outcome(s))
Current secondary outcome measures as of 05/04/2019:
1. Toxicity of radiotherapy assessed by CTCAE (Common Terminology Criteria for Adverse Events)
2. Quality of life
3. Neurocognitive function (UK sites only)
4. Time to second line (salvage) treatment (surgery, radiotherapy, radiosurgery)
5. Time to death (overall survival [OS])
6. Health economic analysis (incremental cost per QALY gained) (UK sites only)

Previous secondary outcome measures:
1. Time to second line (salvage) treatment (surgery, radiotherapy, radiosurgery)
2. Time to death [overall survival (OS)]
3. Toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE)
4. Quality of life is measured using the EORTC C30 and BN20 questionnaires
5. Neurocognitive function is measured using patient testing at baseline and 24 months
6. Health economic analysis (incremental cost per QALY gained) (UK sites only)

Patients will be assessed at baseline, 6 and 12 months following surgery and annually thereafter for a minimum of 5 years post-surgery unless otherwise stated.

Completion date
31/03/2026

Eligibility

Key inclusion criteria
Current inclusion criteria as of 03/05/2017:
1. Histologically confirmed newly diagnosed solitary atypical meningioma (WHO grade II) based on the 2016 WHO criteria
2. Age >/= 16 years
3. All anatomical locations allowed except optic nerve sheath tumour
4. Complete resection (Simpson 1, 2 or 3) as assessed by the surgeon
5. Able to commence radiotherapy between within 12 weeks of surgery (ideally 8-12 weeks)
6. WHO performance status 0, 1 or 2
7. Women of reproductive potential must use effective contraception for the whole duration of the treatment
8. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Previous inclusion criteria:
1. Histologically confirmed newly diagnosed solitary atypical meningioma (WHO grade II) based on the 2007 WHO criteria
2. Age 16 years or over
3. All anatomical locations allowed except optic nerve sheath tumour
4. Complete resection (Simpson grade I, II or III) as assessed by the surgeon
5. Able to commence radiotherapy between 8 and 12 weeks after surgery
6. WHO performance status 0-2

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
157

Key exclusion criteria
Current exclusion criteria as of 05/04/2019:
1. Neurofibromatosis type II (NF-2)
2. Optic nerve sheath tumours
3. Multiple meningiomas
4. Radiation-induced meningioma
5. Clinical evidence of second malignancy, except for cervix carcinoma in situ or basal cell carcinoma, and history of invasive malignancy unless treated with curative intent and the patient

has been disease free for the last five years
6. Previous intracranial tumour in the last 10 years treated with radiotherapy or chemotherapy
7. Pregnant or lactating women.

Previous exclusion criteria as of 03/05/2017:
1. Neurofibromatosis type II (NF-2)
2. Optic nerve sheath tumours
3. Multiple meningiomas
4. Radiation-induced meningioma
5. Clinical evidence of second malignancy, except for cervix carcinoma in situ or basal cell carcinoma, and history of invasive malignancy unless treated with curative intent and the patient has not been disease free for the last five years
6. Previous intracranial tumour
7. Pregnant or lactating women

Previous exclusion criteria:
1. Neurofibromatosis type II (NF-2)
2. Multiple meningiomas
3. Previous radiotherapy to the brain or meninges interfering with the protocol treatment plan
4. Clinical evidence of second malignancies, except a history of cervix carcinoma in situ and/or basal cell carcinoma
5. Pregnant or lactating women

Date of first enrolment
28/04/2016

Date of final enrolment
26/05/2021

Locations

Countries of recruitment
United Kingdom

England

Northern Ireland

Scotland

Wales

Australia

Austria

Belgium

France

Germany

Ireland

Italy

New Zealand

Spain

Switzerland

Study participating centre
The Walton Centre
Liverpool
United Kingdom
L9 7LJ

Study participating centre
Queen's Hospital
Romford
United Kingdom
RM7 0AG

Study participating centre
CHU UCL Namur – Site Sainte-Elisabeth
Namur
Belgium
5000

Study participating centre
Nottingham City Hospital
Nottingham
United Kingdom
NG5 1PB

Study participating centre
Addenbrooke's Hospital
Cambridge
United Kingdom
CB2 0QQ

Study participating centre
Churchill Hospital
Oxford
United Kingdom
OX3 7LE

Study participating centre
Salford Royal Hospital
Manchester
United Kingdom
M6 8HD

Study participating centre
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels
Belgium
1000

Study participating centre
University College London Hospital
London
United Kingdom
NW1 2BU

Study participating centre
Western General Hospital
Edinburgh
United Kingdom
EH4 2XU

Study participating centre
Bristol Haematology and Oncology Centre
Bristol
United Kingdom
BS2 8ED

Study participating centre

Universitaur Ziekenhuis Antwerpen
Antwerp
Belgium
2650

Study participating centre
Medical University Vienna - General Hospital AKH
Vienna
Austria
1090

Study participating centre
Charing Cross Hospital (Imperial College)
London
United Kingdom
W6 8RF

Study participating centre
Onze Lieve Vrouw Ziekenhuis
Aalst
Belgium
-

Study participating centre
University Hospital Southampton NHS Foundation Trust
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre
King's College Hospital NHS Foundation Trust
Denmark Hill
Brixton
London
United Kingdom
SE5 9RS

Study participating centre
Complejo Hospitalario de Navarra
Pamplona
Spain
-

Study participating centre
Plymouth Hospitals NHS Trust
Derriford Road
Crownhill
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol
Barcelona
Spain
-

Study participating centre
Royal Brisbane and Women’s Hospital
Brisbane
Australia
-

Study participating centre
Institut Catala d'Oncologia - ICO Girona - Hospital Doctor Josep Trueta
Girona
Spain
-

Study participating centre
Liverpool Hospital
Sydney
Australia
-

Study participating centre

Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN

Study participating centre
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
Paris
France
-

Study participating centre
UniversitaetsSpital Zurich
Zurich
Switzerland
-

Study participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Royal Hallamshire Hospital
Glossop Rd
Sheffield
United Kingdom
S10 2JF

Study participating centre
CHRU Lille
Lille
France
-

Study participating centre
NHS Greater Glasgow & Clyde
1055 Great Western Rd
Glasgow
United Kingdom
G12 0XH

Study participating centre
Universitaetsspital Basel
Basel
Switzerland
-

Study participating centre
Royal North Shore Hospital
Sydney
Australia
-

Study participating centre
SLRON Beaumont
Dublin
Ireland
-

Study participating centre
Peter MacCallum Cancer Centre
Melbourne
Australia
-

Study participating centre
CHU Lyon - Hopital neurologique Pierre Wertheimer
Lyon
France
-

Study participating centre
Waikato Hospital
Hamilton
New Zealand
-

Study participating centre

Christchurch Hospital
Christchurch
New Zealand
-

Study participating centre
Ospedale Bellaria
Bologna
Italy
-

Study participating centre
Paracelsus Kliniken
Germany
-

Study participating centre
University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Hospital Birmingham
Mindelsohn Way
Edgbaston
Birmingham
United Kingdom
B15 2GW

Study participating centre
Belfast Health and Social Care Trust
Belfast City Hospital
Lisburn Road
Belfast
United Kingdom
BT9 7AB

Study participating centre
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie
Geneva
Switzerland
-

Study participating centre
Calvary Mater Newcastle
Newcastle
Australia
-

Study participating centre
Princess Alexandra Hospital
Sydney
Australia
-

Study participating centre
ROPART (Radiation Oncology Princess Alexandra Hospital Raymond Terrace)
Brisbane
Australia
-

Study participating centre
GasthuisZusters Antwerpen - Sint-Augustinus
Antwerp
Belgium
-

Study participating centre
University Hospitals of North Midlands NHS Trust
Royal Stoke University Hospital
Newcastle Road
Stoke-on-Trent
United Kingdom
ST4 6QG

Study participating centre
Cliniques Universitaires Saint-Luc
Brussels
Belgium
-

Study participating centre

Velindre NHS Trust
Unit 2 Charnwood Court Heol Billingsley
Parc
Nantgarw
Cardiff
United Kingdom
CF15 7QZ

Study participating centre
Westmead Hospital
Sydney
Australia
-

Study participating centre
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne
Switzerland
-

Study participating centre
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan
Italy
-

Study participating centre
Institut Catala d'Oncologia - Hospital Duran i Reynals
Barcelona
Spain
-

Study participating centre
Chris O'Brien Lifehouse
Sydney
Australia
-

Study participating centre

Sir Charles Gairdner Hospital
Nedlands
Australia
-

Study participating centre
Universitaetsklinikum Bonn
Bonn
Germany
-

Study participating centre
Hospital Universitario 12 De Octubre
Madrid
Spain
-

Study participating centre
Royal Marsden NHS Foundation Trust
Fulham Road
London
United Kingdom
SW3 6JJ

Study participating centre
Innsbruck Universitaetsklinik
Innsbruck
Austria
-

Sponsor information

Organisation
The Walton Centre NHS Foundation Trust (UK)

ROR
https://ror.org/05cvxat96

Funder(s)

Funder type
Government

Funder Name
Health Technology Assessment Programme

Alternative Name(s)
NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	14/11/2015		Yes	No
HRA research summary			28/06/2023	No	No
Other publications	qualiatative analysis	01/04/2020	12/02/2020	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes